KIR3DL1 and melanoma: In consistency with this study, the combination of KIR3DL1 with less effective Bw4T80 has been reported in primary melanoma patients compared to metastatic patients[31], since KIR3DL1 generates a weaker inhibitory signal when an threonine residue is present at position 80 (Bw4T80).